Can I Take Saw Palmetto with Amlodipine?

The direct answer

There is no dedicated clinical trial testing amlodipine taken together with saw palmetto, so no study can tell you exactly what happens when the two are combined in a real patient. What is established is that amlodipine lowers blood pressure by blocking calcium channels in vascular smooth muscle, and that saw palmetto's proposed alpha-1 adrenergic antagonism could theoretically add a second, independent vasodilatory pathway. Whether that theoretical overlap produces a clinically noticeable blood pressure drop in an individual patient is not established and depends on age, baseline blood pressure control, and concurrent medications. Because of this evidence gap, disclosure to a prescriber and home blood pressure monitoring during the first weeks of co-use are more useful than a blanket reassurance.

Disambiguating the two substances

Amlodipine (brand name Norvasc, generic widely available) is a long-acting dihydropyridine calcium channel blocker. It blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac muscle, lowering peripheral vascular resistance. It is FDA-approved for hypertension, chronic stable angina, and vasospastic angina, typically dosed once daily at 2.5 mg, 5 mg, or 10 mg. It is metabolized primarily by CYP3A4.

Saw palmetto (Serenoa repens) is an herbal dietary supplement, not an FDA-approved drug. Lipophilic berry extracts, usually standardized to 85 to 95 percent fatty acids and sterols, are sold over the counter for BPH-related urinary symptoms, typically 160 mg twice daily or 320 mg once daily. Because it is a supplement, it has not gone through the FDA drug-interaction review process that a new prescription drug undergoes, and available human data on its interactions are limited to a small number of pharmacology studies, several of which studied different herbs or different endpoints than saw palmetto's cardiovascular effects specifically.

What is actually established, versus what is plausible

This is the section where a generic interaction page usually blurs the line between mechanism and proof. Here it is kept separate.

Established

• Amlodipine is cleared primarily via hepatic CYP3A4, and strong CYP3A4 inhibitors (clarithromycin, itraconazole, and others) can raise amlodipine levels meaningfully. This is a well-documented pharmacokinetic interaction class (2017 ACC/AHA Hypertension Guideline) [1].
• Saw palmetto's benefit for BPH symptoms is weak in the largest available trials. The STEP trial (NEJM, N=225) found no meaningful separation from placebo on urinary symptom scores, and the CAMUS trial (JAMA, N=369), which escalated the dose to 960 mg daily, also found no benefit over placebo (STEP trial [10]; a separate randomized trial (CAMUS)). A 2014 Cochrane review of Serenoa repens for BPH (32 trials) reached a similarly unimpressive efficacy conclusion, and did not treat blood pressure as a primary outcome (a Cochrane review).
• Older adults are at elevated risk of orthostatic hypotension from combined antihypertensive burden, independent of any specific supplement. This is a recognized geriatric prescribing concern in the American Geriatrics Society's Beers Criteria (2019 Beers Criteria [9]).
• Home blood pressure monitoring, done correctly (two seated readings, about a minute apart), is generally considered a reliable way to detect a drifting blood pressure trend before it becomes symptomatic.

Plausible but not established

• That saw palmetto's alpha-1 adrenergic antagonism, seen in preclinical and receptor-binding work, translates into a clinically meaningful additive blood-pressure-lowering effect when combined with amlodipine in real patients. This is a mechanistically reasonable hypothesis, not a demonstrated clinical outcome.
• That saw palmetto meaningfully raises bleeding risk when combined with amlodipine specifically. Amlodipine itself has no significant antiplatelet activity, so any bleeding-risk discussion here is really about saw palmetto alone, and the strength of that signal in humans is not well quantified. One pharmacology study did examine saw palmetto's effect on warfarin and digoxin pharmacokinetics in healthy volunteers and reported no significant pharmacokinetic interaction (a small pharmacology study), which is reassuring for drug-level interactions but does not directly resolve the separate question of platelet function.

Not established, and flagged for verification rather than presented as fact

A version of this page previously cited a laboratory study for the claim that saw palmetto extract inhibits thromboxane production in human platelets. On review, the paper behind that citation is an in-vitro study of Serenoa repens-derived myristoleic acid inducing apoptosis in prostate cancer cells, a different mechanism and endpoint entirely (a laboratory study later found to address an unrelated mechanism). It does not support a platelet-function claim, so that specific claim has been removed rather than repeated. Readers and clinicians should treat any antiplatelet effect of saw palmetto as mechanistically plausible (based on other, separate literature not confirmed here) but not demonstrated by the source used on this page.

Similarly, a claim that a specific 2004 cytochrome P450 study confirmed saw palmetto does not affect CYP3A4 activity was checked against the underlying paper. That study evaluated goldenseal, kava kava, black cohosh, and valerian, not saw palmetto (a study examining other herbs, not saw palmetto). It cannot be used to support a saw-palmetto-specific CYP3A4 conclusion. The Markowitz 2000 study referenced above is a more directly relevant human pharmacokinetic study of saw palmetto, though its focus was warfarin and digoxin rather than amlodipine, so even that finding should be read as suggestive rather than conclusive for amlodipine specifically.

A quoted statement previously attributed to a 2019 AHA scientific statement on supplement-drug interactions could not be verified against a consistent, correctly cited source, because the reference list conflated it with an unrelated heart-failure lifestyle statement. The quotation has been removed. The AHA has published broadly on antihypertensive prescribing and home monitoring, and those documents are cited elsewhere on this page where the connection is direct, but the specific quoted sentence is not retained here pending verification.

A claim describing a 2020 review cataloging post-operative bleeding events tied to saw palmetto also could not be matched to a verifiable, correctly cited source in this draft; the reference list instead pointed to an unrelated nutrition-and-cancer-risk paper. That specific claim has been narrowed: case reports describing bleeding in patients using saw palmetto exist in the broader herbal-medicine literature, but the exact source and details require direct verification before republication.

Evidence-status interaction assessment: amlodipine + saw palmetto

Why the pharmacodynamic concern matters more than the pharmacokinetic one

Amlodipine's long half-life (roughly 30 to 50 hours) means its vasodilatory effect is essentially continuous through the day. If saw palmetto also produces even a mild, continuous vasodilatory effect through alpha-1 antagonism, the two effects would overlap in time rather than compete for the same metabolic enzyme. This is why spacing the two doses apart by a few hours would not be expected to reduce any additive blood-pressure effect. It also explains why the practical monitoring tool is not dose timing but blood pressure tracking over days to weeks.

Bleeding risk: what to actually watch for

Because the specific citation for a saw-palmetto antiplatelet mechanism does not hold up on verification, this page does not assert a quantified bleeding risk. What can be said responsibly:

• Amlodipine has no known clinically significant effect on platelet function.
• Saw palmetto is commonly listed by pharmacists and drug-interaction checkers (such as the Natural Medicines Database and Mayo Clinic's interaction checker) as having a mild bleeding-risk profile, generally rated low severity, though the underlying human evidence base for this rating is thin.
• The practical relevance of any bleeding-risk signal increases sharply if aspirin, clopidogrel, warfarin, or a direct oral anticoagulant is also being taken, or if surgery is planned. Many surgical teams ask patients to stop herbal supplements, including saw palmetto, roughly one to two weeks before an elective procedure, while continuing amlodipine up to the morning of surgery to avoid rebound hypertension. This is a general perioperative principle for herbal supplements rather than a rule specific to this combination, and it should be confirmed with the surgical team.

If you notice unusual bruising or prolonged bleeding from minor cuts after starting saw palmetto, mention it to your prescriber regardless of what medications you are also taking.

A monitoring approach for patients and prescribers

The following is a practical framework for the conversation between a patient and their prescriber or pharmacist. It is not a substitute for individualized medical advice, and it does not set a dose or tell you to start or stop anything.

Before starting saw palmetto while on amlodipine

1. Tell your prescriber your current amlodipine dose and any other blood pressure medications, anticoagulants, or antiplatelets.
2. Record home blood pressure for about a week beforehand as a baseline, using two seated readings a minute apart, per AHA measurement guidance [8].
3. If you take aspirin, clopidogrel, warfarin, or a DOAC, raise the antiplatelet question explicitly, since that is where any bleeding-risk signal would matter most.

During the first four to eight weeks of combined use

• Continue home monitoring at the same frequency.
• Watch for dizziness or lightheadedness on standing, which suggests orthostatic hypotension.
• Note any unusual bruising or bleeding and report it.

If symptoms appear

Sit or lie down first to avoid a fall. Check blood pressure in both positions if a home device is available. Contact your prescriber the same day. Do not stop amlodipine on your own; abrupt discontinuation of a calcium channel blocker can trigger rebound angina in susceptible patients. Your prescriber may adjust the amlodipine dose, order a formal orthostatic blood pressure check, or advise stopping saw palmetto instead.

Weighing the interaction risk against saw palmetto's actual benefit

Before accepting even a small, uncertain interaction risk, it is worth being clear-eyed about what saw palmetto offers. The two largest placebo-controlled trials to date, STEP (NEJM) and CAMUS (JAMA), did not find a meaningful symptom benefit over placebo, even at doses up to 960 mg daily in CAMUS [10][11]. A 2014 Cochrane review reached a similar conclusion across 32 trials [7]. This does not mean saw palmetto is useless for every individual, some men do report subjective improvement, and its general safety profile outside of the concerns discussed here is favorable. But for a patient on amlodipine who is weighing an uncertain benefit against an uncertain interaction risk, prescription alternatives with stronger trial evidence and clearer interaction profiles, such as tamsulosin (an alpha-1 blocker, though it carries its own additive-hypotension concern with amlodipine) or finasteride and dutasteride (5-alpha-reductase inhibitors with no known interaction with amlodipine), are worth discussing with a urologist.

Who should be more cautious

• Adults age 65 and older, per the general orthostatic hypotension concerns raised in the Beers Criteria [9]
• Anyone on more than one antihypertensive medication in addition to amlodipine
• Anyone with a history of fainting or near-fainting episodes
• Anyone taking aspirin, clopidogrel, warfarin, or a DOAC
• Anyone with surgery planned in the next several weeks

Who has a lower-concern profile

• Adults under 65 with no history of dizziness or fainting
• Amlodipine as the only antihypertensive, at 5 mg or lower
• No anticoagulant or antiplatelet medications
• Normal kidney and liver function

If you are already taking both

There is no evidence-based reason to stop either agent abruptly just because you learned about a theoretical interaction. Tell your prescriber at your next visit, review your home blood pressure log for any downward drift since starting saw palmetto, and watch for dizziness, fatigue, or blurred vision on standing. If symptoms are present, your prescriber has several options, including lowering the amlodipine dose, checking orthostatic vitals formally, or advising you to stop the saw palmetto.

When to seek urgent care

Get emergency care immediately if you experience fainting, chest pain, severe or ongoing dizziness, or signs of major bleeding like blood in your stool or urine that does not stop. You should seek evaluation for these symptoms whether or not amlodipine or other supplements are the cause.